期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 40, 期 10, 页码 1111-+出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.21.01252
关键词
-
类别
资金
- Career Pathway Grant in Symptom Management from Conquer Cancer
- ASCO Foundation
- Rising Tide Foundation for Clinical Cancer Research
- Susan G. Komen [CCR17483507]
- Odyssea and Foundation Gustave Roussy
- French Government under the Investment for the Future program [ANR-10-COHO-0004]
- ANR [ANR-18-IBHU-0002]
- Agence Nationale de la Recherche (ANR) [ANR-18-IBHU-0002] Funding Source: Agence Nationale de la Recherche (ANR)
This article presents a predictive model for assessing fatigue among breast cancer survivors. By collecting clinical data from patients, the researchers identified risk factors associated with severe fatigue and developed a predictive model. This is important for early management of fatigue, correcting modifiable risk factors, and providing more accurate monitoring and education for patients at risk of severe post-treatment fatigue.
PURPOSE Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk. PATIENTS AND METHODS Participants with stage I-111 breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score >= 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained associations with severe fatigue by bootstrapped Augmented Backward Elimination. Validation methods included 10-fold internal cross-validation, overoptimism-corrected area under the receiver operating characteristic curves, and external validation. RESULTS Among 5,640, 5,000, and 3,400 patients at T1, T2, and T3, respectively, the prevalence of post-treatment severe global fatigue was 35.6%, 34.0%, and 31.5% in the development cohort. Retained risk factors for severe global fatigue at T2 were severe pretreatment fatigue (adjusted odds ratio v no 3.191 [95% CI, 2.704 to 3.767]); younger age (for 1-year decrement 1.015 [1.009 to 1.022]), higher body mass index (for unit increment 1.025 [1.012 to 1.038]), current smoking behavior (v never 1.552 [1.291 to 1.866]), worse anxiety (v noncase 1.265 [1.073 to 1.492]), insomnia (for unit increment 1.005 [1.003 to 1.007]), and pain at diagnosis (for unit increment 1.014 [1.010 to 1.017]), with an area under the receiver operating characteristic curve of 0.73 (95% CI, 0.72 to 0.75). Receipt of hormonal therapy was a risk factor for severe fatigue at T3 (v no 1.448 [1.165 to 1.799]). Dimension-specific risk factors included body mass index for physical fatigue and emotional distress for emotional and cognitive fatigue. CONCLUSION We propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue. (C) 2022 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据